Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.

Gallwitz B, Guzman J, Dotta F, Guerci B, Simó R, Basson BR, Festa A, Kiljański J, Sapin H, Trautmann M, Schernthaner G

Lancet (London, England)9 Jun 2012Cited by 130 (Europe PMC)

PMID22683137DOI10.1016/s0140-6736(12)60479-6PepBankPUB-22683137

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, exenatide reduced treatment failure compared with glimepiride.
In plain wordsIn patients with diabetes on metformin, exenatide reduced treatment failure compared with glimepiride.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTreatment failure
Study
n = 977
Comparator
glimepiride
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Treatment failure
41%
exenatide
Treatment failure
54%
glimepiride
Risk difference
12.4
exenatide versus glimepiride
Hazard ratio
0.748 ratio
exenatide versus glimepiride
Source sentences
Summary
203 (41%) patients had treatment failure in the exenatide group compared with 262 (54%) in the glimepiride group (risk difference 12·4 [95% CI 6·2-18·6], hazard ratio 0·748 [0·623-0·899]; p=0·002).
2 context sentences(design, population, supporting numbers)
Summary · context
The primary outcome was time to inadequate glycaemic control and need for alternative treatment, defined as an HbA(1c) concentration of more than 9% after the first 3 months of treatment, or more than 7% at two consecutive visits after the first 6 months.
Summary · context
Patients aged 18-85 years with type 2 diabetes inadequately treated by metformin were randomly assigned via a computer-generated randomisation sequence to receive exenatide twice daily or glimepiride once daily as add-on to metformin.
Report a problemFND-2268313701
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, more exenatide recipients than glimepiride recipients achieved HbA1c below 7%.
In plain wordsIn patients with diabetes on metformin, more exenatide recipients than glimepiride recipients achieved HbA1c below 7%.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHbA1c below 7%
Study
n = 977
Comparator
glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Responders
44%
exenatide
Responders
31%
glimepiride
Source sentences
Summary
218 (44%) of 490 patients in the exenatide group, and 150 (31%) of 487 in the glimepiride group achieved an HbA(1c) concentration of less than 7% (p<0·0001), and 140 (29%) versus 87 (18%) achieved concentrations of 6·5% and less (p=0·0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients aged 18-85 years with type 2 diabetes inadequately treated by metformin were randomly assigned via a computer-generated randomisation sequence to receive exenatide twice daily or glimepiride once daily as add-on to metformin.
Report a problemFND-2268313702
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, more exenatide recipients achieved HbA1c of 6.5% or less than glimepiride recipients.
In plain wordsIn patients with diabetes on metformin, more exenatide recipients achieved HbA1c of 6.5% or less than glimepiride recipients.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHbA1c 6.5% or less
Study
n = 977
Comparator
glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
Responders
29%
exenatide
Responders
18%
glimepiride
Source sentences
Summary
218 (44%) of 490 patients in the exenatide group, and 150 (31%) of 487 in the glimepiride group achieved an HbA(1c) concentration of less than 7% (p<0·0001), and 140 (29%) versus 87 (18%) achieved concentrations of 6·5% and less (p=0·0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients aged 18-85 years with type 2 diabetes inadequately treated by metformin were randomly assigned via a computer-generated randomisation sequence to receive exenatide twice daily or glimepiride once daily as add-on to metformin.
Report a problemFND-2268313703
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, exenatide reduced weight more than glimepiride.
In plain wordsIn patients with diabetes on metformin, exenatide reduced weight more than glimepiride.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 977
Comparator
glimepiride
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
We noted a significantly greater decrease in bodyweight in patients given exenatide than in those given glimepiride (p<0·0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients aged 18-85 years with type 2 diabetes inadequately treated by metformin were randomly assigned via a computer-generated randomisation sequence to receive exenatide twice daily or glimepiride once daily as add-on to metformin.
Report a problemFND-2268313704
05HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes, exenatide reduced documented symptomatic hypoglycemia compared with glimepiride.
In plain wordsIn patients with diabetes, exenatide reduced documented low blood sugar with symptoms compared with glimepiride.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseDocumented symptomatic hypoglycemia
Study
n = 977
Comparator
glimepiride
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Significantly fewer patients in the exenatide group than in the glimepiride group reported documented symptomatic (p<0·0001), nocturnal (p=0·007), and non-nocturnal (p<0·0001) hypoglycaemia.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients aged 18-85 years with type 2 diabetes inadequately treated by metformin were randomly assigned via a computer-generated randomisation sequence to receive exenatide twice daily or glimepiride once daily as add-on to metformin.
Report a problemFND-2268313706
06HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes, exenatide reduced nocturnal hypoglycemia compared with glimepiride.
In plain wordsIn patients with diabetes, exenatide reduced nighttime low blood sugar compared with glimepiride.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseNocturnal hypoglycemia
Study
n = 977
Comparator
glimepiride
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Significantly fewer patients in the exenatide group than in the glimepiride group reported documented symptomatic (p<0·0001), nocturnal (p=0·007), and non-nocturnal (p<0·0001) hypoglycaemia.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients aged 18-85 years with type 2 diabetes inadequately treated by metformin were randomly assigned via a computer-generated randomisation sequence to receive exenatide twice daily or glimepiride once daily as add-on to metformin.
Report a problemFND-2268313707
07HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes, exenatide reduced non-nocturnal hypoglycemia compared with glimepiride.
In plain wordsIn patients with diabetes, exenatide reduced low blood sugar outside nighttime compared with glimepiride.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseNon-nocturnal hypoglycemia
Study
n = 977
Comparator
glimepiride
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Significantly fewer patients in the exenatide group than in the glimepiride group reported documented symptomatic (p<0·0001), nocturnal (p=0·007), and non-nocturnal (p<0·0001) hypoglycaemia.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients aged 18-85 years with type 2 diabetes inadequately treated by metformin were randomly assigned via a computer-generated randomisation sequence to receive exenatide twice daily or glimepiride once daily as add-on to metformin.
Report a problemFND-2268313708
08HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes, adverse-event discontinuation was higher with exenatide than glimepiride during the first 6 months.
In plain wordsIn patients with diabetes, more exenatide recipients stopped for adverse events than glimepiride recipients during the first 6 months.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseAdverse-event discontinuation in first 6 months
Study
n = 977
Comparator
glimepiride
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Discontinuation because of adverse events (mainly gastrointestinal) was significantly higher (p=0·0005) in the exenatide group than in the glimepiride group in the first 6 months of treatment, but not thereafter.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients aged 18-85 years with type 2 diabetes inadequately treated by metformin were randomly assigned via a computer-generated randomisation sequence to receive exenatide twice daily or glimepiride once daily as add-on to metformin.
Report a problemFND-2268313709
09HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes, adverse-event discontinuation was not significantly higher with exenatide than glimepiride after the first 6 months.
In plain wordsIn patients with diabetes, adverse-event discontinuation did not significantly differ between treatments after the first 6 months.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeAdverse-event discontinuation after first 6 months
Study
n = 977
Comparator
glimepiride
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Discontinuation because of adverse events (mainly gastrointestinal) was significantly higher (p=0·0005) in the exenatide group than in the glimepiride group in the first 6 months of treatment, but not thereafter.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients aged 18-85 years with type 2 diabetes inadequately treated by metformin were randomly assigned via a computer-generated randomisation sequence to receive exenatide twice daily or glimepiride once daily as add-on to metformin.
Report a problemFND-2268313710
10HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes, five patients in each treatment group died from causes unrelated to treatment.
In plain wordsIn patients with diabetes, five patients in each group died from causes unrelated to treatment.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableDeaths
Study
n: not reported in source
Comparator
glimepiride
Outcome group
Mortality · Whole body
Studied dose
Dose not stated
Measurements
Deaths
5 patients
exenatide
Deaths
5 patients
glimepiride
Source sentences
Summary
Five patients in each treatment group died from causes unrelated to treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients aged 18-85 years with type 2 diabetes inadequately treated by metformin were randomly assigned via a computer-generated randomisation sequence to receive exenatide twice daily or glimepiride once daily as add-on to metformin.
Report a problemFND-2268313705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00359762

Exenatide Versus Glimepiride in Patients With Type 2 Diabetes

AstraZenecan = 1,029Sept 2006 to Mar 2011

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 15 Sept 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.